Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bevacizumab and Immune chEckpoint Inhibitors Plus Hypofractionated Stereotactic radioTherapy for the Treatment of sympTomatic mElanoma bRain Metastases.

NCT06163820 is registered in ClinicalTrials.gov with Melanoma and Skin Cancer Trials Limited as lead sponsor.

NCT NCT06163820
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06163820 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bevacizumab and Immune chEckpoint Inhibitors Plus Hypofractionated Stereotactic radioTherapy for the Treatment of sympTomatic mElanoma bRain Metastases.
Lead sponsor
Melanoma and Skin Cancer Trials Limited
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 31, 2026
Completion date
January 30, 2030
Enrollment
46 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma brain metastases